IRulya Therapeutics Inc. Common Stock
IRLA
42 hedge funds and large institutions have $7.83M invested in IRulya Therapeutics Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
5% more funds holding
Funds holding: 40 → 42 (+2)
3.24% less ownership
Funds ownership: 20.62% → 17.38% (-3.2%)
7% less capital invested
Capital invested by funds: $8.4M → $7.83M (-$576K)
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$134K |
| 2 |
SI
Scharf Investments
Los Gatos,
California
|
+$91.1K |
| 3 |
Jane Street
New York
|
+$44.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$42.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$279K |
| 2 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$56.5K |
| 3 |
Two Sigma Advisers
New York
|
-$22K |
| 4 |
SB
Strategic Blueprint
Atlanta,
Georgia
|
-$13.7K |
| 5 |
LBC
Lawrence B. Cohen
|
-$12.5K |
IRLA Hedge Fund Activity: Q4 2023 in Review
42 of the 6,872 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q4 2023, worth a combined $7.83M — down 6.9% from $8.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IRLA positions and 4 closed out — a net gain of 2 holders — while 4 added to existing stakes and 12 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $134K. The largest seller was Tang Capital Management, cutting an estimated $279K.
- 42 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q4 2023, up from 40 in Q3 2023.
- Funds reported $7.83M of IRulya Therapeutics Inc. Common Stock stock for Q4 2023, down 6.9% quarter-over-quarter.
- 6 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q4 2023 and 4 closed out, a net change of +2 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q4 2023 was Renaissance Technologies, an estimated $134K added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q4 2023 was Tang Capital Management, an estimated $279K sold.
Based on aggregated 13F filings for Q4 2023.